ASCO Selects Ryght AI to Fast Track CDK4/6 Breast Cancer Clinical Trial

If you want to understand just how broken legacy enterprise workflows can be, look no further than the clinical trial industry. Before a life-saving drug ever reaches a pharmacy shelf, it gets bogged down in a multi-billion-dollar administrative swamp. 

The biggest culprit? Study site selection and kickoff, a process still largely dependent on manual spreadsheets, cold outreach, and exhaustive, 40-page feasibility questionnaires sent via email.

Laguna Beach-based healthtech startup Ryght AI thinks agentic AI can fix this. And today, they secured a massive validation milestone from the ultimate enterprise customer in oncology: the American Society of Clinical Oncology (ASCO).

ASCO is integrating Ryght AI’s platform directly into its research infrastructure to fast-track site selection for its upcoming CDK4/6 Inhibitor Dosing Knowledge (CDK) Study. Instead of spending months figuring out which global medical centers have the right staff, equipment, and patient demographics to run the trial, ASCO is letting Ryght’s AI agents do the heavy lifting.

The Tech: Ingesting Protocols, Modeling Twins

While the broader tech ecosystem is arguing over chatbots, Ryght AI is focused on verticalized, agentic workflows for the life sciences. The core of their product is a patent-pending data modeling system called AI Site Twins.

Essentially, Ryght creates dynamic, continuously updated digital twins of every clinical research site globally.

• The Input: A research sponsor uploads a complex, multi-page clinical trial protocol.
• The Processing: Ryght’s generative AI agents parse the document, extracting key operational variables (e.g., required investigator expertise, local regulatory histories, competing trials nearby, and specific patient demographics).
• The Output: The platform instantly crosses this data against its global Site Twins database to deliver a ranked, data-backed list of the best-fit research facilities.

By automating the historical analysis and performance tracking, the platform turns a multi-month guessing game into an instantaneous, data-driven recommendation engine.

Solving a Needle-in-a-Haystack Data Problem

The partnership isn’t just a tech showcase; it’s being deployed to solve a glaring data gap in cancer research.

ASCO’s PCORI-funded CDK study is looking into oral CDK4/6 inhibitors for older adults living with metastatic breast cancer. Even though breast cancer heavily impacts older populations, patients over the age of 75 are notoriously underrepresented in traditional clinical trials. Because of this, doctors are often flying blind when it comes to dose optimization for seniors.

To build a proper evidence base, ASCO needs to find niche, underrepresented patient communities fast. 

“Patients with metastatic breast cancer cannot afford to wait for access to clinical trials,” said Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO. “This collaboration aims to activate the most suitable sites faster and reach more patient communities, helping us more quickly determine the most effective and tolerable doses of CDK4/6 inhibitor therapies to improve patient outcomes.”

Using Ryght’s automated system, ASCO can identify specific global sites that already have access to these exact patient cohorts and the operational capacity to manage them, drastically cutting down enrollment timelines.

“Too many metastatic breast cancer trials lose precious months in slow, manual and error-prone site selection processes,” said Chadi Nabhan, MD, MBA, FACP, Chief Medical Officer and Head of Strategy at Ryght AI, Inc. “Our mission at Ryght is to transform clinical trial timelines by giving research sponsors and networks like ASCO an AI-driven platform that quickly surfaces the right sites for the right studies. When trials open sooner at better sites, patients gain access to innovative therapies at a crucial time, and that is what matters most.”

Rapid Growth from Ryght AI

Ryght has quickly become the dominant player in the AI clinical trial space with several major milestones recently including: the launch RyghtSites, a free clinical trial search engine; and partnerships with major academic hospitals

Its platform has dynamic twins of over 100,000 clinical research sites spanning 192 countries, which it claims can reduce trial site selection from 6 months to just 26 days.  

The company has previously raised $3 million in seed funding round led by Foothill Ventures, AIX Ventures, and others.

Companies can learn more at https://www.ryght.ai/.